hotspot -WSS

hotspot

author：knowledge 2025-09-27 09:58:40 - browse：71

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Lupron, used to halt puberty in children, may cause lasting health problems

explore

WSS

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

A letter from the executive editor: The 2023 STATUS List

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Dexcom's push to bring CGM to type 2 diabetes patients

2 million sign

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Walensky prepares to leave CDC — and Congress — behind

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

New air purifier tech could be key to improving indoor air quality

Being 'nonadherent' patient made me a more empathetic doctor

At least 13 dead in Texas as scorching temps continue

Beware reading your test results before your doctor does

Hepatitis C has a cure — but many Americans still lack access to it

Hubble vs. James Webb telescope images: See the difference

leisure time

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

What affirmative action's end means to a medical student

Condition critical? Britain's beloved but battered National Health Service turns 75

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

AstraZeneca lung cancer study comes in below expectations

explore

knowledge

explore

hotspot